| For: | Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. World J Gastrointest Surg 2022; 14(6): 528-537 [PMID: 35979416 DOI: 10.4240/wjgs.v14.i6.528] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i6/528.htm |
| Number | Citing Articles |
| 1 |
Arash Najafi. Commentary on “Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness”. CardioVascular and Interventional Radiology 2024; 47(7) doi: 10.1007/s00270-024-03794-x
|
| 2 |
Jian-Bo Zhang. Efficacy and safety of transcatheter arterial chemoembolization combined with sorafenib and sintilimab in the treatment of unresectable hepatocellular carcinoma. American Journal of Translational Research 2024; 16(12) doi: 10.62347/KNIV1276
|
| 3 |
Qianyu Xie, Shunchi Xu, Shenji Li, Zhenfang Liu. SAPCD2 High Expression Predicts Transarterial Chemoembolization Response and Prognosis in Hepatocellular Carcinoma: A Retrospective Study. Journal of Surgical Research 2026; 325 doi: 10.1016/j.jss.2026.05.010
|
| 4 |
Haohao Lu, Bin Liang, Chuansheng Zheng, Xiangwen Xia. Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-04419-4
|
| 5 |
Xiao-Bo Cheng, Li Yang, Ming-Qian Lu, Yi-Bo Peng, Lei Wang, Shuang-Ming Zhu, Zhi-Wei Hu, Zhong-Liang Wang, Qin Yang. Clinical study of different interventional treatments for primary hepatocellular carcinoma based on propensity-score matching. World Journal of Gastrointestinal Surgery 2024; 16(11): 3463-3470 doi: 10.4240/wjgs.v16.i11.3463
|
| 6 |
Yun Tao, Wenhui Yu, Wenge Yang, Qinghua Wu, Jie Li. Combining Transarterial Chemoembolisation With Reduced Deubiquitinase Activity Reduces Hepatocellular Carcinoma Progression. Journal of Cellular and Molecular Medicine 2026; 30(12) doi: 10.1111/jcmm.71209
|
| 7 |
Liyan Huang, Qinqin Long, Qunying Su, Xiaoying Zhu, Xidai Long. Aflatoxin B1-DNA adducts modify the effects of post-operative adjuvant transarterial chemoembolization improving hepatocellular carcinoma prognosis. Exploration of Targeted Anti-tumor Therapy 2023; doi: 10.37349/etat.2023.00167
|
| 8 |
Long-Wang Lin, Kun Ke, Le-Ye Yan, Rong Chen, Jing-Yao Huang. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1178428
|
| 9 |
Liyang Yang, Disi Liu, Shanshan Yang, Jiewen Chen, Ge Wen. Preoperative Prediction of TACE Refractoriness in Hepatocellular Carcinoma Using CT-Based Radiomics Model. Journal of Hepatocellular Carcinoma 2026; doi: 10.2147/JHC.S587246
|
| 10 |
Peijie Xia, Aibing Xu, Siyuan Tian, Honghua Huang, Miao Ouyang, Shengnan Huang, Hu Xu. Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma Patients. Hepatitis Monthly 2026; 26(1) doi: 10.5812/hepatmon-168214
|
| 11 |
Landon L. Chan, Stephen L. Chan. The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment. Clinical and Molecular Hepatology 2023; 29(4) doi: 10.3350/cmh.2023.0114
|
| 12 |
Imam Waked, Sherif Alsammany, Sayed Hammad Tirmazy, Kakil Rasul, Jafar Bani‐Issa, Wael Abdel‐Razek, Ashraf Omar, Amr Shafik, Salem Eid, Amr Abdelaal, Ahmed Hosni, Gamal Esmat. Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region. Liver International 2023; 43(10) doi: 10.1111/liv.15685
|
| 13 |
Xinhao Wang, Yefa Yang. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases. Medicine 2024; 103(20) doi: 10.1097/MD.0000000000038174
|
| 14 |
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology 2023; 20(12) doi: 10.1038/s41571-023-00825-3
|
| 15 |
Fuwen Pang, Haihui Deng, Deti Peng, Jian He, Weicheng Zhao, Liqian Yu, Tuantuan Chen, Zonggui Xie, Huawei Cai, Bin Chen. Theranostic radionuclides labeled biodegradable microspheres for the treatment of hepatocellular carcinoma with radioembolization. Radiation Physics and Chemistry 2025; 232 doi: 10.1016/j.radphyschem.2025.112642
|